PY
Live price temporarily unavailable.
Price history
Pyxis Oncology (PYXS) is a Health Care company. Latest news and coverage below.
IPO: October 8, 2021 · $16.00 offering · NASDAQ · View IPO details →
Pyxis Oncology revenue & net income history (FY2020–FY2025)
RevenueNet income
| FY2020Dec 2020 | FY2021Dec 2021 | FY2022Dec 2022 | FY2023Dec 2023 | FY2024Dec 2024 | FY2025Dec 2025 | |
|---|---|---|---|---|---|---|
| Income statement | ||||||
| Revenue | — | — | — | — | $16.1M | $13.9M |
| Growth (year over year) | — | — | — | — | — | −14.2% |
| Gross profit | — | — | — | — | $15.7M | $11.5M |
| Gross margin | — | — | — | — | 97.1% | 82.8% |
| Operating income | −$12.9M | −$69.7M | −$123.5M | −$82.2M | −$89.5M | −$84.4M |
| Operating margin | — | — | — | — | −554.1% | −609.2% |
| Net income | −$12.8M | −$76.0M | −$120.7M | −$73.8M | −$77.3M | −$79.6M |
| Net margin | — | — | — | — | −478.9% | −574.5% |
| EPS (diluted) | −$12.45 | −$8.95 | −$3.65 | −$1.85 | −$1.32 | −$1.28 |
| Balance sheet | ||||||
| Cash and equivalents | $8.08M | $274.7M | $179.3M | $9.66M | $19.5M | $15.4M |
| Total assets | $10.2M | $280.0M | $211.4M | $173.7M | $157.2M | $91.5M |
| Total liabilities | $3.85M | $18.7M | $50.6M | $48.0M | $36.4M | $38.1M |
| Shareholders' equity | −$15.6M | $261.3M | $160.8M | $125.7M | $120.8M | $53.4M |
| Cash flow | ||||||
| Operating cash flow | −$10.1M | −$35.3M | −$89.3M | −$70.7M | −$57.7M | −$63.5M |
| Capital expenditure | $1.48M | $540.0K | $6.40M | $6.73M | $237.0K | $9.00K |
| Free cash flow | −$11.6M | −$35.9M | −$95.7M | −$77.4M | −$57.9M | −$63.5M |
RevenueNet income
| Q3 FY24†Sep 2024 | Q4 FY24Dec 2024 | Q1 FY25†Mar 2025 | Q2 FY25Jun 2025 | Q3 FY25†Sep 2025 | Q4 FY25Dec 2025 | Q1 FY26Mar 2026 | Q2 FY26Jun 2026 | |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $0 | — | $0 | $2.82M | $0 | — | — | — |
| Growth (year over year) | — | — | −100.0% | — | — | — | — | — |
| Gross profit | $0 | — | — | — | — | — | — | — |
| Operating income | −$23.8M | — | −$22.9M | −$19.8M | −$23.5M | — | −$24.4M | −$26.0M |
| Operating margin | — | — | — | −700.4% | — | — | — | — |
| Net income | −$21.2M | — | −$21.2M | −$18.4M | −$22.0M | — | −$23.3M | −$25.3M |
| Net margin | — | — | — | −650.9% | — | — | — | — |
| EPS (diluted) | −$0.35 | — | −$0.35 | −$0.30 | −$0.35 | — | −$0.37 | −$0.40 |
| Balance sheet | ||||||||
| Cash and equivalents | $12.1M | $19.5M | $12.8M | $10.7M | $8.92M | $15.4M | $5.77M | $18.9M |
| Total assets | $195.3M | $157.2M | $135.9M | $123.2M | $105.6M | $91.5M | $64.3M | $54.9M |
| Total liabilities | $41.6M | $36.4M | $32.8M | $35.6M | $36.8M | $38.1M | $33.0M | $43.5M |
| Shareholders' equity | $153.7M | $120.8M | $103.1M | $87.6M | $68.8M | $53.4M | $31.3M | $11.4M |
| Cash flow | ||||||||
| Operating cash flow | −$14.7M | — | −$22.5M | −$17.3M | −$13.3M | — | −$26.0M | −$18.2M |
| Capital expenditure | $0 | — | — | — | — | — | — | — |
| Free cash flow | −$14.7M | — | — | — | — | — | — | — |
From Pyxis Oncology's 10-K and 10-Q filings with the SEC; its fiscal year ends in December. Each period shows the latest figure the company has reported for it, including restatements. † Quarter derived from the company's year-to-date or full-year totals. Filings on SEC EDGAR →
About Pyxis Oncology
- Headquarters
- Boston, Massachusetts From SEC filings, Oct 2026
Recent News (1)
More Health Care stocks
- ILMN Illumina
- A Agilent Technologies
- ABBV AbbVie
- ABT Abbott Laboratories
- ALGN Align Technology
- ALNY Alnylam Pharmaceuticals
- AMGN Amgen
- BAX Baxter International